Last Price
0.161
Today's Change
+0.065 (67.70%)
Day's Change
0.147 - 0.219
Trading Volume
562,826,499
Overview
Market Cap
17 Million
Shares Outstanding
108 Million
Avg Volume
1,074,631
Avg Price (50 Days)
0.13
Avg Price (200 Days)
0.32
PE Ratio
-1.05
EPS
-0.15
Earnings Announcement
27-Mar-2025
Previous Close
0.10
Open
0.18
Day's Range
0.1473 - 0.2194
Year Range
0.08 - 1.23
Trading Volume
565,083,001
Price Change Highlight
1 Day Change
65.99%
5 Day Change
31.44%
1 Month Change
23.03%
3 Month Change
20.03%
6 Month Change
-52.56%
Ytd Change
-82.86%
1 Year Change
-80.30%
3 Year Change
-98.41%
5 Year Change
-98.41%
10 Year Change
-98.41%
Max Change
-98.41%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
Apps
Top Articles
1
CEO Morning Brief
2
CEO Morning Brief
Ben & Jerry's Says Parent Unilever Silenced It Over Gaza Stance
3
CEO Morning Brief
JPMorgan’s Kelly Says Trump Tariffs to Hit Growth, Fan Inflation
4
5
CEO Morning Brief
Bitcoin Briefly Tops US$93,000 on Trump Agenda, Fed Policy Outlook
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
